Peripheral vascular disease
Methodology & AI Transparency ⓘ
Peripheral vascular disease Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Physicians managing Peripheral vascular disease (I73.9; High Blood Pressure & Vascular Health) utilize renal-electrolyte panels [Peripheral vascular disease I73.9] and objective Home Seated Blood in Peripheral vascular disease (I73.9: Pressure) targets (< 120/75 mmHg (I73.9)) to prevent progression and functional morbidity.
- 2 Real-world patient consensus: Federal ICD-10-CM code I73.9 categorizes Peripheral vascular disease under High Blood Pressure & Vascular Health.
- 3 Typical cash cost range: Clinicians assessing Peripheral vascular disease focus on venous valve incompetence [Peripheral vascular disease I73.9] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Peripheral vascular disease: maintaining Home Seated Blood in Peripheral vascular disease (I73.9: Pressure) within < 120/75 mmHg (I73.9).
Ask our AI Specialists anything about Peripheral vascular disease
What Is Peripheral vascular disease?
Physicians managing Peripheral vascular disease (I73.9; High Blood Pressure & Vascular Health) utilize renal-electrolyte panels [Peripheral vascular disease I73.9] and objective Home Seated Blood in Peripheral vascular disease (I73.9: Pressure) targets (< 120/75 mmHg (I73.9)) to prevent progression and functional morbidity.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Peripheral vascular disease (I73.9) features venous valve incompetence [Peripheral vascular disease I73.9]. therapeutic stabilization in blood pressure is verified against Ankle-Brachial Index (ABI) [Peripheral vascular disease I73.9].
Common Symptoms & Clinical Signs
- • Presentation of Peripheral vascular disease (I73.9): cold distal extremities in Peripheral vascular disease (I73.9: or diminished peripheral)
- • Secondary Peripheral vascular disease clinical sign: persistently elevated home in Peripheral vascular disease (I73.9: or clinic blood)
- • Symptom flares in Peripheral vascular disease correlating with Home Seated Blood in Peripheral vascular disease (I73.9: Pressure) deviation outside < 120/75 mmHg (I73.9)
- • Functional blood pressure impact requiring renal-electrolyte panels [Peripheral vascular disease I73.9] evaluation (I73.9)
Peripheral vascular disease Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I73.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NLM Clinical Tables |
| Diagnostic / Lab Marker: Home Seated Blood in Peripheral vascular disease (I73.9: Pressure) | < 120/75 mmHg (I73.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Peripheral vascular disease I73.9] | 1.00 – 1.30 (I73.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Creatinine & in Peripheral vascular disease (I73.9: Potassium) | K+ 4.0 – 4.8 mEq/L (I73.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Peripheral vascular disease
Treatment selection for Peripheral vascular disease depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Peripheral vascular disease)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effects of Mind-Body Exercise on Cognitive Function and Peripheral Blood BDNF in: What a 1,251-Participant Study Found Mind-body exercise is beneficial for improving global cognitive function, verbal fluency, executive function, episodic memory, and short-term memory in older adults with MCI; however, evidence remains insufficient regarding... Geriatrics & gerontology international • 2026-11-15 • Meta-Analysis | N = 1,251 | 94/100 | PMID 42951347 ↗ |
| New Insights on Calmangafodipir for Prevention of Oxaliplatin-Induced Peripheral Neuropathy: Two: What a 301-Participant Study Found The POLAR clinical studies failed to meet their primary endpoint. JNCI cancer spectrum • 2022-11-01 • Phase III Randomized Trial | N = 301 | 93/100 | PMID 36308441 ↗ |
| New Insights on Semaglutide and walking capacity in people with symptomatic peripheral artery: What a 396-Participant Study Found Semaglutide increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes. Lancet (London, England) • 2025-05-03 • Phase III Randomized Trial | N = 396 | 93/100 | PMID 40169145 ↗ |
| New Insights on Quality of life outcomes with a new sustained‑release pregabalin in a phase 3: What a 296-Participant Study Found Once-daily SR pregabalin (YHD1119) achieved QoL outcomes comparable to twice-daily IR pregabalin across general health status, sleep interference, and global impressions over 12 weeks. Current medical research and opinion • 2026-07-15 • Phase III Randomized Trial | N = 296 | 93/100 | PMID 42622433 ↗ |
| New Insights on Characteristics and long-term follow-up of participants with peripheral arterial: What a 830-Participant Study Found Neither amlodipine nor lisinopril showed superiority over chlorthalidone in reducing clinically advanced PAD risk. Journal of general internal medicine • 2014-11-15 • Randomized Controlled Trial | N = 830 | 93/100 | PMID 25002161 ↗ |
Peripheral vascular disease Patient Community & “People Like Me” Threads
Filter Peripheral vascular disease community threads and patient logs by age, biological sex, dosage, and treatment duration.